AI assistant
EXACT Therapeutics AS — Proxy Solicitation & Information Statement 2026
May 29, 2026
3600_rns_2026-05-29_3a1adb13-1d90-4608-9d36-bdc1a91af8d2.html
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
EXACT Therapeutics - Notice for Annual General Meeting 2026
EXACT Therapeutics - Notice for Annual General Meeting 2026
OSLO, May 29 2026: The Annual General Meeting of EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), will be held as a virtual meeting at 10:30 CEST on June 12, 2026.
The formal notice of the Annual General Meeting is attached and provides further information on the proceedings.
The documents are also available at www.exact-tx.com.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email [email protected]
John M. Edminson, CFO
EXACT Therapeutics
Email: [email protected]
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com